Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4142V | ISIN: US48669G3039 | Ticker-Symbol:
NASDAQ
10.10.25 | 16:28
7,170 US-Dollar
+0,70 % +0,050
Branche
Pharma
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
KAZIA THERAPEUTICS LIMITED ADR Chart 1 Jahr
5-Tage-Chart
KAZIA THERAPEUTICS LIMITED ADR 5-Tage-Chart

Aktuelle News zur KAZIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiKazia Therapeutics signs deal for novel cancer immunotherapy asset2
DiKazia Therapeutics sichert sich Lizenz für neuartigen Immunonkologie-Wirkstoff2
DiKazia Therapeutics Limited: Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program118SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration...
► Artikel lesen
02.10.Kazia: Prüfpräparat erzielt 86 % Tumorreduktion bei Brustkrebs-Patientin1
02.10.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer2
02.10.Kazia reports 86% tumor reduction in expanded access case1
02.10.Kazia Therapeutics Limited: Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen64SYDNEY, Oct. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction...
► Artikel lesen
30.09.KAZIA THERAPEUTICS LTD - F-1, Registration statement for certain foreign private issuers2
KAZIA THERAPEUTICS Aktie jetzt für 0€ handeln
11.09.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer6
25.07.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer3
10.07.Kazia Therapeutics stock price target raised to $13 from $2 at H.C. Wainwright-
09.07.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
09.07.Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps3
09.07.Kazia Therapeutics stock soars after positive early cancer treatment data6
09.07.Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase ...282SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial...
► Artikel lesen
11.06.Paxalisib von Kazia zeigt vielversprechende Ergebnisse in präklinischer Brustkrebsstudie13
11.06.Kazia Therapeutics Limited: Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)405SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics...
► Artikel lesen
05.06.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
05.06.Kazia Therapeutics Limited: Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer340Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve...
► Artikel lesen
28.05.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer2
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1